Gina Mauro - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Gina Mauro's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Gina Mauro
Verified
Vice President of Content, OncLive
Jersey Shore
Beats
u.s. politics campaign finance state politics local american religion
Homosexuality, LGBT.
Content
By Gina Mauro| ONCOLOGY journal Verified The use of artificial intelligence (AI)–supported mammography screening was feasible, safe, and more likely to detect breast cancer compared with a standard double reader approach, according to results of the real-world PRAIM trial (DRKS00027322) that were published in Nature Medicine.1,2 Findings showed that the breast cancer detection rate was 6.7 per 1000 women screened, which was a relative increase of 17.6% (95% CI, +5.7% to +30.8%) and statistically superior to the 5.7 per 1000 rate...
By Gina Mauro| ONCOLOGY journal Verified China’s National Medical Products Administration (NMPA) granted approval to the combination of enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda) as a treatment for adult patients with locally advanced or metastatic urothelial cancer, according to a press release from the developer, Astellas Pharma Inc.1 The approval is based on findings from the phase 3 EV-302 trial (NCT04223856), which showed that the combination of enfortumab vedotin and pembrolizumab showed a statistically...
By Gina Mauro| ONCOLOGY journal Verified The use of artificial intelligence (AI)–supported mammography screening was feasible, safe, and more likely to detect breast cancer compared with a standard double reader approach, according to results of the real-world PRAIM trial (DRKS00027322) that were published in Nature Medicine.1,2 Findings showed that the breast cancer detection rate was 6.7 per 1000 women screened, which was a relative increase of 17.6% (95% CI, +5.7% to +30.8%) and statistically superior to the 5.7 per 1000 rate...
Company Info
OncLive
NeurologyLive is a multimedia platform focused on delivering the latest news and insights in the field of neurology. It serves as a valuable resource for healthcare professionals, particularly those treating neurological diseases. The platform offers a combination of print and digital media, ensuring that busy clinicians stay informed about significant developments in neurology. The services provided by NeurologyLive include breaking news on drug approvals, clinical trials, and emerging trends in neurological care. It features expert interviews with leading neurologists, offering insights into the latest research and clinical practices. The use of multimedia content makes the information accessible and engaging for its audience. NeurologyLive targets healthcare professionals such as neurologists, clinicians, and researchers. It has established strategic partnerships with organizations like the Consortium of Multiple Sclerosis Centers, enhancing its credibility and reach within the neurology community. Its comprehensive coverage and expert engagement position NeurologyLive as a trusted source for the latest developments in the field.
Cranbury, United States
+1 609-716-7777
Founded: 2018